Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Thromb Haemost. 2019 Jul 28;17(10):1772–1778. doi: 10.1111/jth.14564

Table.

Khorana risk scores

Patient characteristics Risk score
Site of cancer
 Very high risk (stomach, pancreases) 2
 High risk (lung, lymphoma, gynecologic, bladder, testicular) 1
Pre-chemotherapy platelet count ≥ 350×109/L 1
Hemoglobin level < 10 mg/mL or use of red cell growth factors 1
Pre-chemotherapy leukocyte count > 11 ×109/L 1
BMI ≥ 35 kg/m2 1
*

The AVERT study used a modified Khorana to include patients with brain tumor as very high risk cancer (risk score of 2) and myeloma and kidney cancer as high risk cancer (risk score of 1).